Letter to the Editor
Thalidomide, the story goes on
Talidomida, la historia continúa
a Servicio de Farmacología Clínica, Hospital Universitari Germans Trias i Pujol i Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Badalona, Barcelona, Spain
b Universitat Autònoma de Barcelona (UAB), Cerdanyola del Vallès, Barcelona, Spain
c Servicio de Neonatología, ICGON, Hospital Clínic-Maternitat, IDIBAPS, Barcelona, Spain
d Universidad de Barcelona, Barcelona, Spain
Read
2120
Timeswas read the article
677
Total PDF
1443
Total HTML
Share statistics
array:23 [ "pii" => "S2341287923001023" "issn" => "23412879" "doi" => "10.1016/j.anpede.2023.03.007" "estado" => "S300" "fechaPublicacion" => "2023-06-01" "aid" => "3429" "copyright" => "Asociación Española de Pediatría" "copyrightAnyo" => "2023" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "An Pediatr (Barc). 2023;98:490-1" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S1695403323000656" "issn" => "16954033" "doi" => "10.1016/j.anpedi.2023.03.005" "estado" => "S300" "fechaPublicacion" => "2023-06-01" "aid" => "3429" "copyright" => "Asociación Española de Pediatría" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "An Pediatr (Barc). 2023;98:490-1" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta al Editor</span>" "titulo" => "Talidomida, la historia continúa" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "490" "paginaFinal" => "491" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Thalidomide, the story goes on" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Esther Papaseit, Magí Farré, Óscar Garcia-Algar" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Esther" "apellidos" => "Papaseit" ] 1 => array:2 [ "nombre" => "Magí" "apellidos" => "Farré" ] 2 => array:2 [ "nombre" => "Óscar" "apellidos" => "Garcia-Algar" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2341287923001023" "doi" => "10.1016/j.anpede.2023.03.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287923001023?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403323000656?idApp=UINPBA00005H" "url" => "/16954033/0000009800000006/v1_202306021130/S1695403323000656/v1_202306021130/es/main.assets" ] ] "itemAnterior" => array:19 [ "pii" => "S2341287923001059" "issn" => "23412879" "doi" => "10.1016/j.anpede.2023.04.011" "estado" => "S300" "fechaPublicacion" => "2023-06-01" "aid" => "3443" "copyright" => "Asociación Española de Pediatría" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "An Pediatr (Barc). 2023;98:488-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letters to the Editor</span>" "titulo" => "About mental health and suicide in children and adolescents" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "488" "paginaFinal" => "489" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Acerca de la salud mental y el suicidio en niños y adolescentes" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Azucena Díez Suárez, Juan José Carballo, Concha Sánchez-Pina" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Azucena" "apellidos" => "Díez Suárez" ] 1 => array:2 [ "nombre" => "Juan" "apellidos" => "José Carballo" ] 2 => array:2 [ "nombre" => "Concha" "apellidos" => "Sánchez-Pina" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1695403323000875" "doi" => "10.1016/j.anpedi.2023.04.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403323000875?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287923001059?idApp=UINPBA00005H" "url" => "/23412879/0000009800000006/v1_202306061300/S2341287923001059/v1_202306061300/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Thalidomide, the story goes on" "tieneTextoCompleto" => true "saludo" => "Dear Editor," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "490" "paginaFinal" => "491" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Esther Papaseit, Magí Farré, Óscar Garcia-Algar" "autores" => array:3 [ 0 => array:3 [ "nombre" => "Esther" "apellidos" => "Papaseit" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 1 => array:3 [ "nombre" => "Magí" "apellidos" => "Farré" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:4 [ "nombre" => "Óscar" "apellidos" => "Garcia-Algar" "email" => array:1 [ 0 => "ogarciaa@clinic.cat" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Servicio de Farmacología Clínica, Hospital Universitari Germans Trias i Pujol i Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Badalona, Barcelona, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Universitat Autònoma de Barcelona (UAB), Cerdanyola del Vallès, Barcelona, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Neonatología, ICGON, Hospital Clínic-Maternitat, IDIBAPS, Barcelona, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Universidad de Barcelona, Barcelona, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Talidomida, la historia continúa" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">It has been almost 10 years since we published an editorial in <span class="elsevierStyleItalic">Anales de Pediatría</span> under the title “Thalidomide: an unfinished history”.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> After this time interval, recently there have been news about the reauthorisation for the marketing of thalidomide in Spain, and, as regards those affected by it, the story remains unfinished 10 years later.</p><p id="par0010" class="elsevierStylePara elsevierViewall">Sixty years after the discovery of the severe teratogenic effects of thalidomide, the drug is once again being marketed in Spain since February 2, 2023 (Spanish Agency of Medicines and Medical Devices, AEMPS).<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> To date it had only been available as a drug subject to special medical control since 1985, a foreign drug and later on an orphan drug for treatment of multiple myeloma authorised by the European Medicines Agency (EMA) since 2001. Its exceptional and controlled use has also been authorised for other diseases, such as erythema nodosum or actinic prurigo, when there are no other treatment options. In multiple myeloma in particular, one of its derivatives, lenalidomide, which is authorised for use in Spain, has been replacing thalidomide in many cases.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Contrary to its initial marketing authorisation, the prescription and dispensation of thalidomide are now restricted to a single authorised indication (first-line treatment, in combination with melphalan and prednisone, in patients with untreated multiple myeloma, aged ≥65 years or ineligible for high-dose chemotherapy) and subject to a strict pregnancy prevention programme (PPE) and controlled access system (AEMPS)<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a>: the same surveillance and control system established for thalidomide analogues with more recent marketing authorisations, such as lenalidomide and pomalidomide.</p><p id="par0020" class="elsevierStylePara elsevierViewall">In fact, the system calls for strict safety requirements, and it is similar to the one established by the Food and Drug Administration (FDA) to prevent teratogenicity, the System for Thalidomide Education and Prescribing Safety (STEPS), which was implemented in 1998 with the initial approval in the United States of thalidomide as an orphan drug for treatment of erythema nodosum, which was then extended to multiple myeloma.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> It is worth mentioning that, paradoxically, in the 1960s the United States had rejected the initial application submitted by Chemie Grünenthal for the marketing of thalidomide for symptomatic treatment of nausea and vomiting during pregnancy due to a lack of safety data.</p><p id="par0025" class="elsevierStylePara elsevierViewall">We ought to remember that the teratogenic effects that affected more than 10,000 newborns worldwide marked a turning point in the process of authorization and marketing of drugs for human use, setting the foundations of the current system for monitoring the safety of drugs pre and post marketing (drug surveillance) and specifically recommendations concerning use during pregnancy and/breastfeeding (international classification of pregnancy categories for drugs based on foetal risk). These are indispensable principles today for conducting preclinical and clinical research on new drugs.</p><p id="par0030" class="elsevierStylePara elsevierViewall">Still, what has happened in the past 10 years to the individuals affected by thalidomide in Spain?</p><p id="par0035" class="elsevierStylePara elsevierViewall">At present, in our country, contrary to Germany, the Netherlands or Portugal, where all thalidomide victims have been awarded compensation, the Association of Victims of Thalidomide of Spain (AVITE) is still fighting to gain recognition for affected survivors (more than 300) and compensation for individuals born with malformations known to result from thalidomide exposure between the 1950s and 1985 (Royal Decree of 2018).<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> Financial support payments should have been effected in 2019, but the benefits were never paid due to noncompliance with Law 6/2018 on the General State Budget. In response to this, AVITE filed a suit against the government and the state, but since the cassation appeal was dismissed by the Supreme Court of Spain, it has announced future demonstrations once the political campaigns for the upcoming elections start to claim the payment of due compensations.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">The story goes on…</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Talidomida: una historia inacabada" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "E. Papaseit" 1 => "O. García-Algar" 2 => "M. Farré" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.anpedi.2012.11.022" "Revista" => array:6 [ "tituloSerie" => "An Pediatr (Barc)" "fecha" => "2013" "volumen" => "78" "paginaInicial" => "283" "paginaFinal" => "287" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23333198" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Ficha técnica talidomida [Accessed 20 February 2023]. Available from: <a target="_blank" href="https://cima.aemps.es/cima/pdfs/ft/85082/FT_85082.pdf">https://cima.aemps.es/cima/pdfs/ft/85082/FT_85082.pdf</a>." ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Comercialización de talidomida: Programa de Prevención de Embarazo y Sistema de Acceso Controlado [Accessed 20 February 2023]. Available from: <a target="_blank" href="https://www.aemps.gob.es/informa/comercializacion-de-talidomida-programa-de-prevencion-de-embarazo-y-sistema-de-acceso-controlado/">https://www.aemps.gob.es/informa/comercializacion-de-talidomida-programa-de-prevencion-de-embarazo-y-sistema-de-acceso-controlado/</a>." ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.B. Zeldis" 1 => "B.A. Williams" 2 => "S.D. Thomas" 3 => "M.E. Elsayed" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/s0149-2918(00)88289-2" "Revista" => array:6 [ "tituloSerie" => "Clin Ther" "fecha" => "1999" "volumen" => "21" "paginaInicial" => "319" "paginaFinal" => "330" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10211535" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Asociación de Víctimas de Talidomida de España (AVITE) [Accessed 20 February 2023]. Available from: <a target="_blank" href="https://www.avite.org/postura-de-avite-ante-el-anuncio-del-regreso-de-la-talidomida/">https://www.avite.org/postura-de-avite-ante-el-anuncio-del-regreso-de-la-talidomida/</a>." ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/23412879/0000009800000006/v1_202306061300/S2341287923001023/v1_202306061300/en/main.assets" "Apartado" => array:4 [ "identificador" => "95838" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/23412879/0000009800000006/v1_202306061300/S2341287923001023/v1_202306061300/en/main.pdf?idApp=UINPBA00005H&text.app=https://analesdepediatria.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287923001023?idApp=UINPBA00005H" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 October | 64 | 45 | 109 |
| 2024 September | 53 | 50 | 103 |
| 2024 August | 63 | 62 | 125 |
| 2024 July | 44 | 37 | 81 |
| 2024 June | 64 | 37 | 101 |
| 2024 May | 61 | 54 | 115 |
| 2024 April | 45 | 40 | 85 |
| 2024 March | 48 | 23 | 71 |
| 2024 February | 100 | 35 | 135 |
| 2024 January | 77 | 27 | 104 |
| 2023 December | 81 | 21 | 102 |
| 2023 November | 120 | 45 | 165 |
| 2023 October | 117 | 34 | 151 |
| 2023 September | 115 | 29 | 144 |
| 2023 August | 64 | 22 | 86 |
| 2023 July | 84 | 26 | 110 |
| 2023 June | 113 | 47 | 160 |
| 2023 May | 130 | 43 | 173 |
Show all
